OMONTYS Drug Patent Profile
✉ Email this page to a colleague
When do Omontys patents expire, and when can generic versions of Omontys launch?
Omontys is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and fourteen patent family members in thirty-four countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Omontys
Omontys was eligible for patent challenges on March 27, 2016.
Indicators of Generic Entry
Summary for OMONTYS
International Patents: | 114 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 18 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OMONTYS at DailyMed |
Recent Clinical Trials for OMONTYS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Amgen | Phase 4 |
Affymax | Phase 3 |
Takeda | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for OMONTYS
US Patents and Regulatory Information for OMONTYS
OMONTYS is protected by six US patents.
Patents protecting OMONTYS
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Expired US Patents for OMONTYS
International Patents for OMONTYS
See the table below for patents covering OMONTYS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20060022239 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | ⤷ Try a Trial |
Georgia, Republic of | P20135981 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USAGE THEREOF | ⤷ Try a Trial |
European Patent Office | 1917023 | PREPARATIONS DE PEPTIDES AGONISTES DU RECEPTEUR DE L'ERYTHROPOIETINE ET UTILISATIONS (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES) | ⤷ Try a Trial |
Eurasian Patent Organization | 200702656 | СОСТАВЫ, СОДЕРЖАЩИЕ ПЕПТИДЫ, СТИМУЛИРУЮЩИЕ РЕЦЕПТОР ЭРИТРОПОЭТИНА, И ИХ ПРИМЕНЕНИЕ | ⤷ Try a Trial |
Hong Kong | 1088616 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | ⤷ Try a Trial |
Eurasian Patent Organization | 200501800 | НОВЫЙ РАЗДЕЛИТЕЛЬНЫЙ ФРАГМЕНТ (СПЕЙСЕР) ДЛЯ МОДИФИЦИРОВАННЫХ ПОЛИЭТИЛЕНГЛИКОЛЕМ СОЕДИНЕНИЙ НА ОСНОВЕ ПЕПТИДОВ | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2004100997 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |